Guggenheim Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL)

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “buy” rating reissued by equities research analysts at Guggenheim in a note issued to investors on Friday,Benzinga reports.

A number of other research analysts also recently weighed in on VIGL. William Blair assumed coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They set an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Vigil Neuroscience in a research note on Thursday. JMP Securities reissued a “market outperform” rating and set a $22.00 price objective on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Finally, Wedbush boosted their target price on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vigil Neuroscience currently has an average rating of “Buy” and an average price target of $19.75.

Vigil Neuroscience Stock Down 6.4 %

NASDAQ:VIGL opened at $2.20 on Friday. Vigil Neuroscience has a twelve month low of $1.49 and a twelve month high of $6.06. The stock has a market cap of $89.94 million, a P/E ratio of -1.07 and a beta of 1.76. The firm’s fifty day simple moving average is $2.08 and its 200 day simple moving average is $3.11.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Thursday, November 7th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.08. On average, analysts expect that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

Hedge funds have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in Vigil Neuroscience in the second quarter valued at about $87,000. Renaissance Technologies LLC increased its holdings in Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after acquiring an additional 11,536 shares in the last quarter. Walleye Capital LLC raised its stake in Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after acquiring an additional 92,217 shares during the period. Verition Fund Management LLC purchased a new position in Vigil Neuroscience during the third quarter valued at approximately $442,000. Finally, Geode Capital Management LLC boosted its position in shares of Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock worth $769,000 after purchasing an additional 66,712 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.